Effect of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation on Quality of Life in Chronic Cancer Pain

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorThe Third Affiliated hospital of Zhejiang Chinese Medical University

About this trial

This study aims to objectively evaluate the effect of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation (PC-TEAS) on improving the quality of life in patients with chronic cancer pain, thereby providing evidence-based medical support for its efficacy and offering practical basis for patients to achieve home-based auxiliary treatment based on their own needs. Furthermore, by observing and comparing changes in indicators such as pain-related scores, analgesic consumption, emotional scores, spontaneous bowel movements, and adverse events, this research will comprehensively assess the advantages of PC-TEAS in the management of chronic cancer pain and explore other potential benefits of this intervention for patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age between 18 and 80 years, regardless of gender;

Diagnosis of primary or metastatic malignant tumor confirmed by histopathology and/or cytology, consistent with the American Cancer Society criteria for malignancy;

Presence of cancer-related pain, defined as an average Numeric Rating Scale (NRS) score ≥ 2 over the preceding week or current regular use of opioid analgesics;

Life expectancy ≥ 3 months;

Disqualifiers

Pain not attributable to cancer;

Severe cardiopulmonary dysfunction or respiratory depression;

Implantation of cardiac pacemaker or metallic implants at stimulation sites;

Local skin lesions or conditions unsuitable for TEAS at the acupoint sites;

Trial design

Design model

Parallel

Treatments tested in this trial

  • TEAS

    Other intervention

    Patients assumed a supine or sitting position, and after routine skin disinfection at the acupoint sites, one pair of electrode patches was attached to the two ipsilateral acupoints of the same group, with the same procedure performed on the contralateral side. A transcutaneous electrical acupoint stimulator was used to apply TEAS sequentially to acupoint groups ① and ②. Each acupoint group received a single TEAS session lasting 30 minutes. Participants were permitted to undergo multiple TEAS sessions within the same day, with all treatments recorded in a pain diary. The TEAS parameters were set as a continuous wave at a frequency of 2 Hz, with the current intensity adjusted to the patient's tolerance level. The treatment followed a "patient-controlled, as-needed" administration pattern. Each treatment course lasted 7 days, with a minimum of 3 treatment days per course and a total of no fewer than 5 sessions per course. A total of 4 treatment courses were conducted.

  • sham TEAS

    Other intervention

    Participants were informed that, due to individual variations in sensory thresholds, it is normal if no distinct sensation is perceived even at the maximum stimulation intensity. Regardless of subjective perception, the transcutaneous electrical acupoint stimulation treatment remains active and exerts its therapeutic effects continuously.

Treatment groups

290 Participants
are divided into 2 treatment groups
Group A: TEAS Intervention GroupExperimental treatment 1 intervention
Group B: Sham TEAS Control GroupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

The area under the curve (AUC) of the FACT-G (Functional Assessment of Cancer Therapy - General) total score for assessing quality of life in patients with chronic cancer pain after 4 weeks of treatment.

the FACT-G comprises 27 items grouped into 4 domains: physical well-being, social/family well-being, emotional well-being, and functional well-being; some items require reverse scoring, with the total score ranging from 0 to 108. Higher scores indicate better quality of life. Using the area under the curve scoring method allows for the observation of the cumulative benefit of PC-TEAS usage in patients over the entire treatment period

Time frame
Baseline; Week 1; Week 2; Week 3;Week 4; Week 8; Week 12

Secondary outcomes

1

the changes in BPI score from baesline

The Brief Pain Inventory (BPI) is primarily used to assess pain severity and its multidimensional impact on patients' quality of life. The scale consists of two core components: BPI-S (Pain Severity) and BPI-I (Pain Interference). The BPI-S quantifies the severity of pain through four items: average pain, worst pain, least pain, and current pain intensity. The BPI-I evaluates the degree to which pain interferes with daily functioning across seven domains: mobility, activities of daily living, work, sleep, relationships with others, enjoyment of life, and mood, thereby providing a comprehensive multidimensional reflection of pain's impact on patient quality of life.Scores range from 0-10, with higher scores indicating more severe pain

Time frame
Baseline; Week 4; Week 8; Week 12
2

Dosage of analgesics used on the assessment days

Changes in the amount of analgesic use from baseline

Time frame
Baseline; Week 4; Week 8 ; Week 12
3

Spontaneous bowel movements (SBM) during assessment days

Spontaneous bowel movements (SBM) refer to bowel movements that occurred in the past 24 hours without the use of rescue laxatives. The number of spontaneous bowel movements by the subjects in the past week was recorded.

Time frame
Baseline; Week 4; Week 8; Week 12
4

Bowel Function Index (BFI) during assessment days

The Bowel Function Index (BFI) is a clinical tool specifically designed to assess opioid-induced constipation. It records the patient's ratings over the past week for straining during defecation, sense of incomplete bowel evacuation, and overall satisfaction with the bowel movement process.

Time frame
Baseline; Week 4; Week 8; Week 12

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.